Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

J. T. Larsen, Shaji K Kumar, Angela Dispenzieri, R. A. Kyle, J. A. Katzmann, S Vincent Rajkumar

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

A markedly elevated serum free light chain (FLC) ratio may serve as a biomarker for malignant transformation in high-risk smoldering multiple myeloma (SMM) and identify patients who are at imminent risk of progression. We retrospectively studied the predictive value of the serum (FLC) assay in 586 patients with SMM diagnosed between 1970 to 2010. A serum involved/uninvolved FLC ratio ≥100 was used to define high-risk SMM, which included 15% (n=90) of the total cohort. Receiver operating characteristics analysis determined the optimal FLC ratio cut-point to predict progression to symptomatic multiple myeloma (MM) within 2 years of diagnosis, which resulted in a specificity of 97% and sensitivity of 16%. Fifty-six percent of patients developed progressive disease during median follow-up of 52 months, but this increased to 98% in the subgroup of patients with FLC ratio ≥100. The median time to progression in the FLC ratio ≥100 group was 15 months versus 55 months in the FLC <100 group (P<0.0001). The risk of progression to MM within the first 2 years in patients with an FLC ratio ≥100 was 72%; the risk of progression to MM or light chain amyloidosis in 2 years was 79%. We conclude that a high FLC ratio ≥100 is a predictor of imminent progression in SMM, and such patients may be considered candidates for early treatment intervention.

Original languageEnglish (US)
Pages (from-to)941-946
Number of pages6
JournalLeukemia
Volume27
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Multiple Myeloma
Biomarkers
Light
Serum
Amyloidosis
ROC Curve
Sensitivity and Specificity

Keywords

  • biomarker
  • free light chain ratio
  • prognosis
  • smoldering multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. / Larsen, J. T.; Kumar, Shaji K; Dispenzieri, Angela; Kyle, R. A.; Katzmann, J. A.; Rajkumar, S Vincent.

In: Leukemia, Vol. 27, No. 4, 04.2013, p. 941-946.

Research output: Contribution to journalArticle

@article{c1c02b029f1e4c7dab372cd7d726cf3c,
title = "Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma",
abstract = "A markedly elevated serum free light chain (FLC) ratio may serve as a biomarker for malignant transformation in high-risk smoldering multiple myeloma (SMM) and identify patients who are at imminent risk of progression. We retrospectively studied the predictive value of the serum (FLC) assay in 586 patients with SMM diagnosed between 1970 to 2010. A serum involved/uninvolved FLC ratio ≥100 was used to define high-risk SMM, which included 15{\%} (n=90) of the total cohort. Receiver operating characteristics analysis determined the optimal FLC ratio cut-point to predict progression to symptomatic multiple myeloma (MM) within 2 years of diagnosis, which resulted in a specificity of 97{\%} and sensitivity of 16{\%}. Fifty-six percent of patients developed progressive disease during median follow-up of 52 months, but this increased to 98{\%} in the subgroup of patients with FLC ratio ≥100. The median time to progression in the FLC ratio ≥100 group was 15 months versus 55 months in the FLC <100 group (P<0.0001). The risk of progression to MM within the first 2 years in patients with an FLC ratio ≥100 was 72{\%}; the risk of progression to MM or light chain amyloidosis in 2 years was 79{\%}. We conclude that a high FLC ratio ≥100 is a predictor of imminent progression in SMM, and such patients may be considered candidates for early treatment intervention.",
keywords = "biomarker, free light chain ratio, prognosis, smoldering multiple myeloma",
author = "Larsen, {J. T.} and Kumar, {Shaji K} and Angela Dispenzieri and Kyle, {R. A.} and Katzmann, {J. A.} and Rajkumar, {S Vincent}",
year = "2013",
month = "4",
doi = "10.1038/leu.2012.296",
language = "English (US)",
volume = "27",
pages = "941--946",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

AU - Larsen, J. T.

AU - Kumar, Shaji K

AU - Dispenzieri, Angela

AU - Kyle, R. A.

AU - Katzmann, J. A.

AU - Rajkumar, S Vincent

PY - 2013/4

Y1 - 2013/4

N2 - A markedly elevated serum free light chain (FLC) ratio may serve as a biomarker for malignant transformation in high-risk smoldering multiple myeloma (SMM) and identify patients who are at imminent risk of progression. We retrospectively studied the predictive value of the serum (FLC) assay in 586 patients with SMM diagnosed between 1970 to 2010. A serum involved/uninvolved FLC ratio ≥100 was used to define high-risk SMM, which included 15% (n=90) of the total cohort. Receiver operating characteristics analysis determined the optimal FLC ratio cut-point to predict progression to symptomatic multiple myeloma (MM) within 2 years of diagnosis, which resulted in a specificity of 97% and sensitivity of 16%. Fifty-six percent of patients developed progressive disease during median follow-up of 52 months, but this increased to 98% in the subgroup of patients with FLC ratio ≥100. The median time to progression in the FLC ratio ≥100 group was 15 months versus 55 months in the FLC <100 group (P<0.0001). The risk of progression to MM within the first 2 years in patients with an FLC ratio ≥100 was 72%; the risk of progression to MM or light chain amyloidosis in 2 years was 79%. We conclude that a high FLC ratio ≥100 is a predictor of imminent progression in SMM, and such patients may be considered candidates for early treatment intervention.

AB - A markedly elevated serum free light chain (FLC) ratio may serve as a biomarker for malignant transformation in high-risk smoldering multiple myeloma (SMM) and identify patients who are at imminent risk of progression. We retrospectively studied the predictive value of the serum (FLC) assay in 586 patients with SMM diagnosed between 1970 to 2010. A serum involved/uninvolved FLC ratio ≥100 was used to define high-risk SMM, which included 15% (n=90) of the total cohort. Receiver operating characteristics analysis determined the optimal FLC ratio cut-point to predict progression to symptomatic multiple myeloma (MM) within 2 years of diagnosis, which resulted in a specificity of 97% and sensitivity of 16%. Fifty-six percent of patients developed progressive disease during median follow-up of 52 months, but this increased to 98% in the subgroup of patients with FLC ratio ≥100. The median time to progression in the FLC ratio ≥100 group was 15 months versus 55 months in the FLC <100 group (P<0.0001). The risk of progression to MM within the first 2 years in patients with an FLC ratio ≥100 was 72%; the risk of progression to MM or light chain amyloidosis in 2 years was 79%. We conclude that a high FLC ratio ≥100 is a predictor of imminent progression in SMM, and such patients may be considered candidates for early treatment intervention.

KW - biomarker

KW - free light chain ratio

KW - prognosis

KW - smoldering multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84876141787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876141787&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.296

DO - 10.1038/leu.2012.296

M3 - Article

VL - 27

SP - 941

EP - 946

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -